NCT05122975View on ClinicalTrials.gov

Treatment of an Inherited Ventricular Arrhythmia

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

April 1, 2024

Study Completion Date

April 1, 2024

Conditions
Catecholaminergic Polymorphic Ventricular Tachycardia Type 1
Interventions
DRUG

S48168 (ARM210)

Ryanodine Receptor modulator

DRUG

Matching Placebo

Placebo of same size and consistency as S48168 (ARM210)

Trial Locations (2)

55905

Mayo Clinic, Rochester

91105

Amsterdam University Medical Center, Amsterdam-Zuidoost

Sponsors

Lead Sponsor

Armgo Pharma, Inc.
All Listed Sponsors
lead

Armgo Pharma, Inc.

INDUSTRY

NCT05122975 - Treatment of an Inherited Ventricular Arrhythmia | Biotech Hunter | Biotech Hunter